News

A group of scientists have raised a hypothesis that the measles, mumps, and rubella (MMR) vaccine could protect children from COVID-19.

Women with premature ovarian insufficiency become estrogen deficient at an early age, which makes them more vulnerable to the loss of bone mineral density. A new study suggests that the use of continuous combined oral contraceptives may be effective in reducing bone mass loss.

Researchers have discovered that a cell signaling pathway called the heat shock protein cascade may offer new drugs for tuberous sclerosis complex, a neurological disorder that results in non-cancerous tumors.

Scientists from Uppsala University describe how they have been able to predict how drug molecules that can be used against cancer bind to G-protein-coupled receptors.

According to new research, patients undergoing active cancer treatment who develop COVID-19 don’t fare any worse than other hospitalized patients.

New research has revealed novel insights into the molecular circuitry controlling the growth and spread of cancer. The researchers have uncovered new pathways involved in these key processes of cancer progression that may hold potential as therapeutic targets.

Scientists have created a next-generation drug "Ciapavir" that is effective at reactivating dormant human immunodeficiency virus (HIV). The research aims to create a functional HIV cure by activating and then eliminating all "pockets" of dormant HIV.

Bubble-like structures, made with just protein and RNA, could potentially be engineered to deliver drugs, researchers say.

A new precision drug targeting cancer’s ability to repair its DNA has shown promising results in a clinical trial. The study, designed to test the drug’s safety, found that half of the participants given the new drug either alone or with platinum chemotherapy saw their cancer stop growing, and two participants saw their tumors shrink or disappear completely.

A major Phase 3 trial of capivasertib, a cancer drug has begun. The trial will enrol ~830 patients across 20 countries and will examine the effects of the drug in premenopausal or postmenopausal women, and men, with an advanced form of oestrogen receptor-positive, human epidermal growth factor receptor 2 negative breast cancer.